Database release 2018.3

Our third database release of the year, 2018.3, is now available. This update contains the following new features and content changes:

Content updates

GPCRs:
Adenosine receptors
Chemokine receptors
Cholecystokinin receptors
Dopamine receptors
Ghrelin receptors
Opioid receptors
GPR55 receptors

NHRs:
MRetinoic acid receptor

Channels:
Transient Receptor Potential channels
voltage-gated sodium channels

Enzymes:
Guanylyl cyclases (GCs)
Janus kinase (JakA) family
Mitogen-activated protein kinases (MAP kinases)
Nitric oxide synthases

Catalytic Receptors:
Natriuretic peptide receptor family

Transporters:
ABCG subfamily
Monoamine transporter subfamily

Others:
CD molecules

Anti-malarial data

The existing Antimalarial targets family has been updated with 5 new P. falciparum (3D7) targets:

• PfATP4 (Plasmodium falciparum ATPase4)
• PfDHFR-TS (Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase)
• PfDXR (Plasmodium falciparum 1-deoxy-D-xylulose 5-phosphate reductoisomerase)
• PfeEF2 (Plasmodium falciparum elongation factor 2)
• PfPI4K (Plasmodium falciparum phosphatidylinositol 4-kinase)

A new Antimalarial ligands family has been created and contains 30 ligands all tagged as an antimalarial in the database. Of these 30, 20 are new ligands curated for this release.

New website features

GtoImmuPdb now public

The IUPHAR Guide to IMMUNOPHARMACOLOGY is now at its first public release and is no longer considered a beta version. We will continue to develop the portal and specific immuno interfaces as well as continuing curation towards its official launch in October 2018. This will be at the BPS Immunopharmacology: Challenges, opportunities and research tools meeting in Edinburgh, 1st-2nd October 2018.

Disease Summary Pages

The disease summary pages have been modified to improve the payout of target information and provide links to help to understand terms and symbols. The display of associated ligand is now in a sortable table and the comments section includes bioactivity comments where present. We have also include links to the specific clinical data or bio-activity tabs on ligand summary pages.